Partnering for Innovation in Manufacturing & Supply

How are bio/pharma companies and their partners collaborating to resolve the difficult challenges that arise in development, manufacturing, and the supply chain? DCAT Member Companies are invited to apply to share fresh insights, best practices, and lessons learned at a DCAT Week program. Applications close January 13, 2025.

How are bio/pharma companies and their partners collaborating to resolve the difficult challenges that arise in development, manufacturing, and the supply chain? DCAT Member Companies are invited to apply to share fresh insights, best practices, and lessons learned at a DCAT Week program. Applications deadline extended and closes January 24, 2025.

By Patricia Van Arnum, Editorial Director, DCAT, pvanarnum@dcat.org

A solutions-based program at DCAT Week
Innovation is essential for achieving operational excellence and delivering value. A DCAT Week 2025 program, Partnering for Innovation in Manufacturing & Supply, will feature case studies on how bio/pharma companies and their partners have collaborated to resolve the hard challenges that arise in development, manufacturing, and the supply chain. Partner companies include CDMOs/CMOs, suppliers of raw materials or other inputs, technology services providers, or other companies, including other bio/pharma companies.

The 90-minute program will consist of three co-presentations (20 minutes each) between a bio/pharma company and partner company. It is a way to share fresh insights, best practices, and lessons learned to a well-informed business audience of senior to mid-level executives.

DCAT Member Companies are invited to submit applications by January 24, 2025, for consideration of their case study.  A task force of industry colleagues selected from DCAT volunteer committees and leadership will evaluate all applications and select three case studies providing the most useful, valuable, and innovative insight of utility and interest to DCAT Member Companies. Presentations will be due March 3, 2025. Further information, including the online application to apply, may be found here.

Topics of interest
The case studies may address a range of topics—but must reflect an innovative or better approach taken in manufacturing or supply. Potential topics can include:

  • New technologies in drug-substance and drug-product manufacturing or packaging;
  • Cost optimization and improved production economics;
  • Collaborative project management;
  • Increasing supply-chain performance, resiliency, or visibility;
  • Upgraded inventory management;
  • Collaborative demand and supply planning/forecasting;
  • Sustainability improvements: technology, manufacturing & metrics;
  • Digitalization to better performance, including regulatory compliance; or
  • Other innovation in manufacturing and supply.

The program provides a way to stand out among your peers in the industry by showing  resourceful and effective ways to advance manufacturing and supply. Further information, including the online application to apply, may be found here.

Recent Feature Articles

Small-Molecule CDMO Outlook: What Lies Ahead

By
At the mid-point in 2026, how are small-molecule CDMOs faring? Larger CDMOs are faring well while CDMOs in early-stage capabilities face some headwinds with more challenging biotech financing

Biotech IPOs: Who Is Topping the Class of 2026?

By
What companies are topping biotech IPOs in 2026? Parabilis Medicines with a focus on alpha-helical peptides and Kailera Therapeutics specializing in GLP-1s and related drugs for obesity are leading the way. By Patricia Van…

China: The Innovation Factor Coming Into Play

By
Pfizer’s $10.5-billion partnering deal with China’s Innovent Biologics is the latest deal between the bio/pharmaceutical majors and China-based innovator drug companies. Is China becoming a force in innovation?

Oncology Drug Market: The Ups and Downs 

By
ASCO’s Annual Meeting, held this week in Chicago, is when bio/pharma companies highlight the most promising in their cancer drug pipelines and portfolios. What is the outlook for the global oncology drug market?